Accuray - Cowealth Arbitration Ruling Delivered SUNNYVALE, Calif., Nov. 4, 2015 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the International Chamber of Commerce International Court of Arbitration (ICC) issued an interim award in an arbitration filed by Cowealth Medical Holding Co., Ltd., Accuray's former distributor, alleging wrongful termination by Accuray of the parties' agreement to distribute the CyberKnife® System in China. Cowealth had originally sought damages of approximately $170 million from Accuray as well as injunctive relief. The ICC verdict awarded Cowealth damages of approximately $3.4 million, while denying Cowealth's claim for injunctive relief. Accuray won three of its counterclaims, which are critical to its business operations in China, including the right to be assigned the existing service contracts between Cowealth and Accuray customers. In addition, Cowealth must transfer to Accuray any regulatory clearances, licenses or permits obtained and held for the purposes of selling the CyberKnife System in China and deliver any consigned parts in their possession. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees. Under the terms of the ICC Rules of Arbitration all awards are binding and cannot be appealed by either party. In accordance with generally accepted accounting principles (GAAP) Accuray will record an additional $3.4 million of operating expenses in the first quarter of 2016. This expense will be incremental to the Company's financial results for the first quarter of 2016 as announced on October 29, 2015 and will be reflected in the financial statements included in the Company's quarterly report on Form 10-Q for the first quarter of 2016, to be filed no later than November 6, 2015. Accuray is not adjusting its previously issued guidance for fiscal 2016. "As described in our most recent Form 10-K, we expected a ruling between October 2015 and February 2016. With the interim award issued, we are excited about our commercial opportunities in China and the potential to provide patients with access to precise, clinically proven, leading-edge radiation therapy," said Joshua H. Levine, president and chief executive officer of Accuray.
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
F-合富(4745)Q3營收看增，全年拼增一成上看35億元 財訊新聞 2015/07/23 09:36 【財訊快報／何美如報導】F-合富(4745)第二季營收下滑，主要係首季有一台放射腫瘤設備入帳，及部分供應商違約影響。下半年除違約供應商有機會返還，合資合作、檢驗試劑銷售續增溫，眼科產品銷售也開始放量，顯像放療系統ViewRay也有機會賣出，業績將逐季增溫，第三季也將優於第二季，全年營收拼增10%挑戰35億元。而與Accuray的仲裁案，合富主張8000萬美元之違約損失。該仲裁案已在1月26日到2月6日於香港經仲裁庭審理，合富指出，目前正靜候仲裁結果，原本認為，結果最快會在第三季出爐，不過，根據Accuray先前公告，仲裁結果可能會延至今年10月至明年2月才會有結果。第二季營收7.72億元，季衰退約13.8%，主要係首季有一台放射腫瘤設備入帳，及部分供應商違約影響，預估每股盈餘約1.2元。合富表示，已針對供應商違約行為提出告訴，爭取供應商履行合約，並於5月開庭，預計第三季判決會出爐。中國反腐打貪在短期造成決策者放慢決策速度，但合富表示，從客戶續約情況來看，今年檢驗試劑應能維持15-16%的年增長幅度。合資合作業務也將有大幅度增長，新簽合作合約至少可為今年帶來新台幣3億元的營收，以淨利率15%計算，至少可貢獻4500萬元淨利，每股貢獻度約0.8元。眼科設備今年在中國、台灣銷售也將在下半年放量，中國預計第三季取得檢查設備的產品註冊，今年出貨將挑戰50套，而台灣市場目標在醫療院所達一成的滲透率，出貨量挑戰70套。而ViewRay今年出售第一台的可能性不低。法人預估，下半年除違約供應商有機會返還，眼科產品銷售開始放量，合資合作、檢驗試劑銷售續增溫，業績將逐季向上，第三季將優於第二季，全年營收可望達35億元，年成長一成。
Posts
No comments:
Post a Comment